1. Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years
- Author
-
Cufer, Tanja, Ovcaricek, Tanja, and O’Brien, Mary E.R.
- Subjects
- *
CANCER chemotherapy , *LUNG cancer , *SURVIVAL - Abstract
Abstract: The standard palliative treatment for advanced stage NSCLC remains a platinum doublet but by tailoring chemotherapy according to tumour histology the results can be improved through using pemetrexed-containing schemas in non-squamous-cell disease. In addition, maintenance chemotherapy appears to be effective in patients achieving clinical benefit by induction therapy. Targeted therapy based on the presence of activating epidermal growth factor receptor (EGFR) activating mutations or EML4–ALK gene rearrangement is becoming standard practice with high median survival rates, up to 30months. There are still numerous other molecular targeted drugs in development. This review presents the most recent relevant progress in systemic anti-cancer therapy of advanced NSCLC in the past 5years and delineates today’s new treatment options. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF